

# CITATION REPORT

List of articles citing

The reporting odds ratio and its advantages over the proportional reporting ratio

DOI: 10.1002/pds.1001

Pharmacoepidemiology and Drug Safety, 2004, 13, 519-23.

**Source:** <https://exaly.com/paper-pdf/37070240/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
407	Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint. <b>2004</b> , 292, 2643-6		38
406	Current awareness: Pharmacoepidemiology and drug safety. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2004</b> , 13, i-xii	2.6	
405	The risk of anaphylactic reactions to rocuronium in the United States is comparable to that of vecuronium: an analysis of food and drug administration reporting of adverse events. <b>2005</b> , 101, 819-822		39
404	Evaluation of statistical association measures for the automatic signal generation in pharmacovigilance. <b>2005</b> , 9, 518-27		56
403	The history of disproportionality measures (reporting odds ratio, proportional reporting rates) in spontaneous reporting of adverse drug reactions. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2005</b> , 14, 285-26 <sup>6</sup>		35
402	Perspectives on the use of data mining in pharmaco-vigilance. <b>2005</b> , 28, 981-1007		173
401	Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports. <b>2006</b> , 28, 1123-1132		25
400	Evidence-based guidelines for the utilization of immunostains in diagnostic pathology: pulmonary adenocarcinoma versus mesothelioma. <b>2007</b> , 15, 140-4		26
399	Advances in Statistical Methods for the Health Sciences. <b>2007</b> ,		4
398	Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias. <b>2007</b> , 30, 891-8		147
397	Telithromycin use and spontaneous reports of hepatotoxicity. <b>2007</b> , 30, 697-703		21
396	Gynaecomastia associated with proton pump inhibitors: a case series from the Spanish Pharmacovigilance System. <b>2007</b> , 30, 527-31		17
395	Signal detection methodologies to support effective safety management. <b>2007</b> , 6, 451-64		20
394	Applying quantitative methods for detecting new drug safety signals in pharmacovigilance national database. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2007</b> , 16, 1136-40	2.6	11
393	Analysis of longitudinal laboratory data in the presence of common selection mechanisms: a view toward greater emphasis on pre-marketing pharmaceutical safety. <b>2008</b> , 27, 2248-66		3
392	A signal of increased risk of hypoglycaemia with angiotensin receptor blockers caused by confounding. <b>2008</b> , 66, 142-5		20
391	Allergic reactions to oral drugs: A case/non-case study from an Italian spontaneous reporting database (GIF). <b>2008</b> , 58, 202-7		30

390	Studying the causes of adverse drug reactions: circumvent the warning-interfered bias using the case-case comparison approach. <b>2008</b> , 61, 516	5
389	Safety Signals Using Proportional Reporting Ratios from Company and Regulatory Authority Databases. <b>2008</b> , 42, 205-210	3
388	Signal Detection of Adverse Drug Reactions. <b>2009</b> , 14, 27-36	31
387	Signal Detection of Drug Complications Applying Association Rule Learning for Stevens-Johnson Syndrome. <b>2009</b> , 10, 118-127	5
386	Genotype-phenotype correlates in Taiwanese patients with early-onset recessive Parkinsonism. <b>2009</b> , 24, 104-8	22
385	Prevalence of unilateral tremor in autosomal dominant essential tremor. <b>2009</b> , 24, 108-11	28
384	Serotonin and dopamine transporter genes do not influence depression in Parkinson's disease. <b>2009</b> , 24, 111-5	19
383	Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study. <b>2009</b> , 24, 115-8	16
382	Essential tremor might be less frequent than Parkinson's disease in North Israel Arab villages. <b>2009</b> , 24, 119-22	19
381	Increased oxidative stress in patients with amyotrophic lateral sclerosis/Parkinsonism-dementia complex in the Kii peninsula, Japan. <b>2009</b> , 24, 123-6	9
380	Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. <b>2009</b> , 24, 126-9	67
379	Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. <b>2009</b> , 24, 129-33	48
378	Sonographic substantia nigra hypoechogenicity in polyneuropathy and restless legs syndrome. <b>2009</b> , 24, 133-7	16
377	Quantitative signal detection using spontaneous ADR reporting. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2009</b> , 18, 427-36	2.6 400
376	Statins and amyotrophic lateral sclerosis--the level of evidence for an association. <b>2009</b> , 266, 520-6	12
375	Heart rhythm disturbances associated with rupatadine: a case series from the Spanish and Portuguese pharmacovigilance systems. <b>2009</b> , 85, 481-4	8
374	Effect of date of drug marketing on disproportionality measures in pharmacovigilance: the example of suicide with SSRIs using data from the UK MHRA. <b>2009</b> , 32, 441-7	20
373	Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity. <b>2010</b> , 30, 68-71	43

372	A novel method for signal detection of adverse drug reactions based on proportional reporting ratios. <b>2010</b> , 32, 658-62		1
371	Signal detection of rosuvastatin compared to other statins: data-mining study using national health insurance claims database. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2010</b> , 19, 238-46	2.6	28
370	Selected control events and reporting odds ratio in signal detection methodology. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2010</b> , 19, 1159-65	2.6	23
369	A potential competition bias in the detection of safety signals from spontaneous reporting databases. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2010</b> , 19, 1166-71	2.6	36
368	Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. <b>2010</b> , 70, 721-8		42
367	Sharp bounds on causal effects in case-control and cohort studies. <b>2010</b> , 97, 123-132		5
366	Drug-induced taste and smell alterations: a case/non-case evaluation of an italian database of spontaneous adverse drug reaction reporting. <b>2011</b> , 34, 849-59		36
365	Disease-specific adverse events following nonlive vaccines: a paradoxical placebo effect or a nocebo phenomenon?. <b>2011</b> , 29, 6321-6		9
364	Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. <b>2011</b> , 72, 905-8		210
363	Potential for linezolid-related blindness: a review of spontaneous adverse event reports. <b>2011</b> , 31, 585-90		6
362	A Likelihood Ratio Test Based Method for Signal Detection With Application to FDA's Drug Safety Data. <b>2011</b> , 106, 1230-1241		65
361	Work-related asthma in France: recent trends for the period 2001-2009. <b>2012</b> , 69, 391-7		60
360	Automatic Drug Adverse Reaction Discovery from Parenting Websites Using Disproportionality Methods. <b>2012</b> ,		15
359	Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods. <b>2012</b> , 50, 890-7		64
358	Extracting drug adverse and beneficial reactions in pediatric population from healthcare social network. <b>2012</b> ,		
357	Identifying adverse events of vaccines using a Bayesian method of medically guided information sharing. <b>2012</b> , 35, 61-78		9
356	The role of the KIDS for enhancing drug safety and risk management in Korea. <b>2012</b> , 55, 861		5
355	Spontaneously reported hepatic adverse drug events in Korea: multicenter study. <b>2012</b> , 27, 268-73		25

354	Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 622-30	2.6	11
353	A shrinkage-based comparative assessment of observed-to-expected disproportionality measures. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 589-96	2.6	7
352	Reports of sexual disorders related to serotonin reuptake inhibitors in the French pharmacovigilance database: an example of underreporting. <b>2013</b> , 36, 515-9		4
351	Postmarketing safety surveillance : where does signal detection using electronic healthcare records fit into the big picture?. <b>2013</b> , 36, 183-97		70
350	Mining Adverse Drug Reactions from Electronic Health Records. <b>2013</b> ,		1
349	Tigecycline-related pancreatitis: a review of spontaneous adverse event reports. <b>2013</b> , 33, 63-8		15
348	Drug safety data mining with a tree-based scan statistic. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2013</b> , 22, 517-23	2.6	46
347	The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist. <b>2013</b> , 69 Suppl 1, 33-41		12
346	Likelihood ratio test-based method for signal detection in drug classes using FDA's AERS database. <b>2013</b> , 23, 178-200		22
345	Disproportionality methods for pharmacovigilance in longitudinal observational databases. <b>2013</b> , 22, 39-56		68
344	Systems approaches in risk assessment. <b>2013</b> , 93, 413-24		18
343	Association between acute myelogenous leukemia and thrombopoietin receptor agonists in patients with immune thrombocytopenia. <b>2013</b> , 52, 2193-201		15
342	Data mining of the public version of the FDA Adverse Event Reporting System. <b>2013</b> , 10, 796-803		234
341	Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms. <b>2014</b> , 11, 461-5		7
340	. <b>2014</b> ,		4
339	Analyzing GeoSentinel surveillance data: a comparison of methods to explore acute gastrointestinal illness among international travelers. <b>2014</b> , 58, 546-54		8
338	Pharmacovigilance using observational/longitudinal databases and web-based information. <b>2014</b> , 345-360		
337	Linked vaccine adverse event data from VAERS for biomedical data analysis and longitudinal studies. <b>2014</b> , 7, 36		2

336	Quantitative Signal Detection and Analysis in Pharmacovigilance. <b>2014</b> , 331-354	10
335	Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States. <b>2014</b> , 10, 232-7	22
334	Likelihood ratio based tests for longitudinal drug safety data. <b>2014</b> , 33, 2408-24	15
333	A Review of Statistical Methods for Safety Surveillance. <b>2014</b> , 48, 98-108	25
332	Hepatotoxicity related to agomelatine and other new antidepressants: a case/noncase approach with information from the Portuguese, French, Spanish, and Italian pharmacovigilance systems. <b>2014</b> , 34, 327-30	23
331	Association between an excess risk of acute kidney injury and concomitant use of ibuprofen and acetaminophen in children, retrospective analysis of a spontaneous reporting system. <b>2014</b> , 70, 479-82	21
330	INTERNATIONAL SOCIETY OF PHARMACOVIGILANCE. <b>2014</b> , 37, 831-891	1
329	Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events. <b>2014</b> , 39, 307-13	15
328	Occupational allergic contact dermatitis and major allergens in France: temporal trends for the period 2001-2010. <b>2014</b> , 171, 1375-85	32
327	An Historical Perspective of the Future of Pharmacovigilance. <b>2014</b> , 807-817	
326	Acute kidney injury during concomitant use of valacyclovir and loxoprofen: detecting drug-drug interactions in a spontaneous reporting system. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2014</b> , 23, 1154-9.6	18
325	Identification of sex-associated network patterns in Vaccine-Adverse Event Association Network in VAERS. <b>2015</b> , 6, 33	3
324	Association rule mining in the US Vaccine Adverse Event Reporting System (VAERS). <i>Pharmacoepidemiology and Drug Safety</i> , <b>2015</b> , 24, 922-33	2.6 8
323	Occupational contact urticaria: lessons from the French National Network for Occupational Disease Vigilance and Prevention (RNV3P). <b>2015</b> , 173, 1453-61	36
322	Signal detection in FDA AERS database using Dirichlet process. <b>2015</b> , 34, 2725-42	10
321	Effect of database profile variation on drug safety assessment: an analysis of spontaneous adverse event reports of Japanese cases. <b>2015</b> , 9, 3031-41	35
320	Analysis of Adverse Events Associated with the Anti-Allergic Agents Rx-to-OTC-Switched Using Data Mining of the Japanese Adverse Drug Event Report (JADER) Database. <b>2015</b> , 41, 667-675	1
319	Detection of signals of abuse and dependence applying disproportionality analysis. <b>2015</b> , 71, 229-36	13

318	Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. <b>2015</b> , 80, 285-93	53
317	Role of serotonin 5-HT <sub>2C</sub> and histamine H <sub>1</sub> receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase. <b>2015</b> , 25, 1556-65	44
316	Twenty years of SHIELD: decreasing incidence of occupational asthma in the West Midlands, UK?. <b>2015</b> , 72, 304-10	24
315	Detecting drug-herbal interaction using a spontaneous reporting system database: an example with benzylpenicillin and qingkailing injection. <b>2015</b> , 71, 1139-45	14
314	Methods and Issues to Consider for Detection of Safety Signals From Spontaneous Reporting Databases: A Report of the DIA Bayesian Safety Signal Detection Working Group. <b>2015</b> , 49, 65-75	6
313	Evaluation of statistical methods for safety signal detection: a simulation study. <b>2015</b> , 14, 11-9	4
312	Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone: a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database. <b>2016</b> , 30, 162-71	11
311	Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database. <b>2016</b> , 36, 735-742	31
310	Adverse drug reactions of systemic antihistamines in children in the Netherlands. <b>2016</b> , 101, 968-70	11
309	Statistical Monitoring of Safety in Clinical Trials. <b>2016</b> , 8, 88-105	9
308	Outcome of antiepileptic drug treatment of 1282 patients with epilepsy, their pharmacovigilance reports and concomitant medication on CNS in an East-Hungarian adult database. <b>2016</b> , 369, 220-226	7
307	Adverse Reaction Prediction and Pharmacovigilance of Nutraceuticals: Examples of Computational and Statistical Analysis on Big Data. <b>2016</b> , 239-248	1
306	An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies. <b>2016</b> , 39, 29-43	27
305	Signal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias: A Disproportionality Analysis Using Data from Vigibase(®). <b>2016</b> , 39, 689-96	23
304	What Is the Plural of a 'Yellow' Anecdote?. <b>2016</b> , 39, 1-3	4
303	Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: Results of a pharmacovigilance reporting system. <b>2016</b> , 104, 108-14	37
302	Dipeptidyl Peptidase-4 Inhibitor-Associated Pancreatic Carcinoma: A Review of the FAERS Database. <b>2016</b> , 50, 27-31	17
301	Evaluating the impact of design pattern and anti-pattern dependencies on changes and faults. <b>2016</b> , 21, 896-931	28

300	Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS). <b>2017</b> , 23, 93-102		15
299	Zero-inflated Poisson model based likelihood ratio test for drug safety signal detection. <b>2017</b> , 26, 471-488		15
298	[Antiemetics and cardiac effects potentially linked to prolongation of the QT interval: Case/non-case analysis in the national pharmacovigilance database]. <b>2017</b> , 65, 1-8		10
297	Effect of statins on blood pressure: Analysis on adverse events released by FDA. <b>2017</b> , 39, 325-329		8
296	Data-mining for detecting signals of adverse drug reactions of fluoxetine using the Korea Adverse Event Reporting System (KAERS) database. <b>2017</b> , 256, 237-242		18
295	Logistic Regression Likelihood Ratio Test Analysis for Detecting Signals of Adverse Events in Post-market Safety Surveillance. <b>2017</b> , 27, 990-1008		7
294	Safety of ceftriaxone in paediatrics: a systematic review protocol. <b>2017</b> , 7, e016273		3
293	Adverse drug reactions of montelukast in children and adults. <b>2017</b> , 5, e00341		33
292	Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System. <b>2017</b> , 7, 5527		21
291	MSBIS: A Multi-Step Biomedical Informatics Screening Approach for Identifying Medications that Mitigate the Risks of Metoclopramide-Induced Tardive Dyskinesia. <b>2017</b> , 26, 132-137		4
290	Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database. <b>2017</b> , 27, 1108-1113		47
289	An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders. <b>2017</b> , 83, 612-622		24
288	Differences in VigiBase reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2017</b> , 26, 1-8	2.6	12
287	Clindamycin hydrochloride and clindamycin phosphate: two drugs or one? A retrospective analysis of a spontaneous reporting system. <b>2017</b> , 73, 251-253		2
286	Blood Pressure Elevation Associated with Topical Prostaglandin F <sub>2β</sub> Analogs: An Analysis of the Different Spontaneous Adverse Event Report Databases. <b>2017</b> , 40, 616-620		6
285	Carboplatin-induced hematotoxicity among patients with non-small cell lung cancer: Analysis on clinical adverse events and drug-gene interactions. <b>2017</b> , 8, 32228-32236		11
284	Incidence and physiological mechanism of carboplatin-induced electrolyte abnormality among patients with non-small cell lung cancer. <b>2017</b> , 8, 18417-18423		12
283	Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database. <b>2017</b> , 12, e0182045		9



282	A signal detection method for temporal variation of adverse effect with vaccine adverse event reporting system data. <b>2017</b> , 17, 76		3
281	Evaluation of the Expression Profile of Extrapyrimal Symptoms Due to Antipsychotics by Data Mining of Japanese Adverse Drug Event Report (JADER) Database. <b>2017</b> , 137, 111-120		16
280	Demographic and Socioeconomic Characteristics of Outpatients Could Modify Their Attitude Towards Misusing Medications in Northern Jordan. <b>2017</b> , 6, 818		5
279	Digoxin-induced anemia among patients with atrial fibrillation and heart failure: clinical data analysis and drug-gene interaction network. <b>2017</b> , 8, 57003-57011		7
278	Sensitivity of Quantitative Signal Detection in Regards to Pharmacological Neuroenhancement. <b>2017</b> , 18,		3
277	Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance. <b>2018</b> , 52, 159-169		11
276	Adverse drug event profile associated with pregabalin among patients with and without cancer: analysis of a spontaneous reporting database. <b>2018</b> , 43, 543-549		10
275	Extended likelihood ratio test-based methods for signal detection in a drug class with application to FDA's adverse event reporting system database. <b>2018</b> , 27, 876-890		7
274	Important statistical considerations in the evaluation of post-market studies to assess whether opioids with abuse-deterrent properties result in reduced abuse in the community. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 473-478	2.6	7
273	Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. <b>2018</b> , 19, 1579-1589		395
272	Significance of data mining in routine signal detection: Analysis based on the safety signals identified by the FDA. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 1402-1408	2.6	13
271	Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study. <b>2018</b> , 32, 607-617		7
270	Risk of Hypoglycemia After Concomitant Use of Antidiabetic, Antihypertensive, and Antihyperlipidemic Medications: A Database Study. <b>2018</b> , 58, 1324-1331		5
269	WITHDRAWN: Cognition and Dementia Related Adverse Effects with Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database. <b>2018</b> ,		
268	Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database. <b>2018</b> , 38, 867-872		6
267	Mining Patients' Narratives in Social Media for Pharmacovigilance: Adverse Effects and Misuse of Methylphenidate. <b>2018</b> , 9, 541		18
266	Pillars and Pitfalls of the New Pharmacovigilance Legislation: Consequences for the Identification of Adverse Drug Reactions Deriving From Abuse, Misuse, Overdose, Occupational Exposure, and Medication Errors. <b>2018</b> , 9, 611		11
265	Adverse reaction signal detection methodology in pharmacoepidemiology. <b>2018</b> , 33, 507-508		3

264	Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database. <b>2018</b> , 41, e130-e132	36
263	Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors. <b>2018</b> , 104, 1859-1863	29
262	Signal detection for bleeding associated with the use of direct oral anticoagulants. <b>2018</b> , 75, 973-977	4
261	Analyses of non-benzodiazepine-induced adverse events and prognosis in elderly patients based on the Japanese adverse drug event report database. <b>2018</b> , 4, 10	6
260	Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database. <b>2018</b> , 24, 533-536	9
259	Detecting Pharmacovigilance Signals Combining Electronic Medical Records With Spontaneous Reports: A Case Study of Conventional Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis. <b>2018</b> , 9, 875	13
258	Effect of Lawyer-Submitted Reports on Signals of Disproportional Reporting in the Food and Drug Administration's Adverse Event Reporting System. <b>2019</b> , 42, 85-93	3
257	Relationship of clinical adverse event reports to models of arrhythmia risk. <b>2019</b> , 100, 106622	2
256	Adverse Drug Reaction Risk Measures: A Comparison of Estimates from Drug Surveillance and Randomised Trials. <b>2019</b> , 33, 331-339	3
255	Safety of azithromycin in paediatrics: a systematic review protocol. <b>2019</b> , 3, e000469	3
254	Early signal detection of adverse events following influenza vaccination using proportional reporting ratio, Victoria, Australia. <b>2019</b> , 14, e0224702	5
253	Cataracts and statins. A disproportionality analysis using data from VigiBase. <b>2019</b> , 109, 104509	2
252	Comparison of bleeding risks among non-vitamin K antagonist oral anticoagulants using the Korea adverse event reporting system database. <b>2019</b> , 10, 2042098619876737	3
251	Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database. <b>2019</b> , 145, 1-9	43
250	Cardiovascular Toxicities Associated With Ibrutinib. <b>2019</b> , 74, 1667-1678	85
249	Safety profile of traditional Chinese herbal injection: An analysis of a spontaneous reporting system in China. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 28, 1002-1013	2.6 26
248	Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. <b>2019</b> , 7, 134	137
247	Is TNF inhibitor exposure a risk factor for amyotrophic lateral sclerosis?. <b>2019</b> , 33, 689-694	3

246	Likelihood-Ratio-Test Methods for Drug Safety Signal Detection from Multiple Clinical Datasets. <b>2019</b> , 2019, 1526290	4
245	Analysis of the Association of Administration of various glucocorticoids with development of acute pancreatitis using US Food and Drug Administration adverse event reporting system (FAERS). <b>2019</b> , 5, 5	5
244	Drug-induced hyperglycemia in the Japanese Adverse Drug Event Report database: association of evelolimus use with diabetes. <b>2019</b> , 66, 571-574	6
243	Efficient methods for signal detection from correlated adverse events in clinical trials. <b>2019</b> , 75, 1000-1008	2
242	A Comparison Study of Algorithms to Detect Drug-Adverse Event Associations: Frequentist, Bayesian, and Machine-Learning Approaches. <b>2019</b> , 42, 743-750	17
241	Full Issue PDF. <b>2019</b> , 1, I-CXCII	
240	Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS). <b>2019</b> , 1, 172-178	20
239	Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports. <b>2019</b> , 19, 279	6
238	Rhabdomyolysis risk from the use of two-drug combination of antidiabetic drugs with antihypertensive and antidiabetic medications: a signal detection analysis. <b>2019</b> , 33, 339-346	1
237	Cutaneous adverse drug reactions to psychotropic drugs and their risk factors - a case-control study. <b>2019</b> , 29, 111-121	5
236	Reply to Hardalo et al., "Myelosuppression with Oxazolidinones: Are There Differences?". <b>2019</b> , 63,	
235	Pharmacoepidemiology in the Prevention of Adverse Drug Reactions. <b>2019</b> , 25-65	2
234	Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study. <b>2020</b> , 113, 9-21	15
233	Complementing Observational Signals with Literature-Derived Distributed Representations for Post-Marketing Drug Surveillance. <b>2020</b> , 43, 67-77	2
232	Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization. <b>2020</b> , 18, 192-200.e2	6
231	Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database. <b>2020</b> , 70, 55-59	6
230	Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study. <b>2020</b> , 43, 1315-1322	24
229	A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. <b>2020</b> , 19, 1505-1511	15

228	Uses of pharmacovigilance databases: An overview. <b>2020</b> , 75, 591-598		37
227	Insights from Pharmacovigilance: Gastrointestinal-Related Immune Checkpoint Inhibitor Adverse Events. <b>2020</b> , 159, 1195-1200.e1		2
226	Likelihood Ratio Test Method for Multiple Medical Devices Comparison Using Multiple-Site Data with Continuous Outcomes. <b>2020</b> , 54, 1444-1452		
225	Differences in risk factors for anticoagulant-related nephropathy between warfarin and direct oral anticoagulants: Analysis of the Japanese adverse drug event report database. <b>2021</b> , 87, 2977-2981		
224	Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis. <b>2020</b> , 1-7		6
223	Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase. <b>2020</b> , 142, 2443-2455		43
222	Cardiotoxicity Associated with Gemcitabine: Literature Review and a Pharmacovigilance Study. <b>2020</b> , 13,		5
221	Exploring pharmacogenetic difference using adverse event database: an example of clopidogrel and cardiovascular events. <b>2020</b> , 21, 1157-1168		
220	Predicting Drug Risk Level from Adverse Drug Reactions Using SMOTE and Machine Learning Approaches. <b>2020</b> , 8, 185761-185775		7
219	Extended multi-item gamma Poisson shrinker methods based on the zero-inflated Poisson model for postmarket drug safety surveillance. <b>2020</b> , 39, 4636-4650		2
218	Safety concerns reported by consumers, manufacturers and healthcare professionals: A detailed evaluation of opioid-related adverse drug reactions in the FDA database over 15 years. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2020</b> , 29, 1627-1635	2.6	4
217	Comparison of Data Mining Methods for the Signal Detection of Adverse Drug Events with a Hierarchical Structure in Postmarketing Surveillance. <b>2020</b> , 10,		6
216	Deep Learning for Adverse Event Detection from Web Search. <b>2020</b> , 1-1		3
215	Subset Analysis for Screening Drug-Drug Interaction Signal Using Pharmacovigilance Database. <b>2020</b> , 12,		3
214	Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors. <b>2020</b> , 5,		15
213	. <b>2020</b> ,		
212	T-cell lymphoma secondary to checkpoint inhibitor therapy. <b>2020</b> , 8,		13
211	Antineoplastic Drug-induced Aortitis: An Unraveled Adverse Effect Using the World Health Organization Pharmacovigilance Database. <b>2020</b> , 47, 1298-1300		3

210	A Bayesian hierarchical approach for multiple outcomes in routinely collected healthcare data. <b>2020</b> , 39, 2639-2654	2
209	Association between oral anticoagulants and osteoporosis: Real-world data mining using a multi-methodological approach. <b>2020</b> , 17, 471-479	7
208	Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation. <b>2020</b> , 12,	6
207	Dolutegravir and neural tube defects: a new insight. <b>2020</b> , 20, 405-406	4
206	Signals of Adverse Drug Reactions of Paliperidone Compared to Other Atypical Antipsychotics Using the Korean Adverse Event Reporting System Database. <b>2020</b> , 40, 873-881	1
205	Movement disorders and use of risperidone and methylphenidate: a review of case reports and an analysis of the WHO database in pharmacovigilance. <b>2021</b> , 30, 1047-1058	1
204	Borrowing external information to improve Bayesian confidence propagation neural network. <b>2020</b> , 76, 1311-1319	2
203	Detecting potential signals of adverse drug events from prescription data. <b>2020</b> , 104, 101839	3
202	Towards a comprehensive safety understanding of granulocyte-colony stimulating factor biosimilars in treating chemotherapy associated febrile neutropenia: Trends from decades of data. <b>2020</b> , 395, 114976	6
201	Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database. <b>2020</b> , 14, 139-143	29
200	Bacillus Calmette-Guérin (BCG) vaccine safety surveillance in the Korea Adverse Event Reporting System using the tree-based scan statistic and conventional disproportionality-based algorithms. <b>2020</b> , 38, 3702-3710	3
199	Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. <b>2021</b> , 157, 35-42	24
198	Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System. <b>2021</b> , 44, 107-119	6
197	Risk of haematological events and preventive effect of folic acid in methotrexate users with chronic kidney disease and rheumatoid arthritis: Analysis of the Japanese Adverse Drug Event Report database. <b>2021</b> , 87, 2286-2289	0
196	Renal ischemic adverse drug events related to tranexamic acid in women of child-bearing age: an analysis of pharmacovigilance data. <b>2021</b> , 77, 913-919	2
195	SGLT2 Inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database. <b>2021</b> , 61, 187-192	10
194	Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System. <b>2021</b> , 90, 41-48	27
193	Differences in detected safety signals between benzodiazepines and non-benzodiazepine hypnotics: pharmacovigilance study using a spontaneous reporting system. <b>2021</b> , 18, 1130-1136	2

192	Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. <b>2021</b> , 26, 341-348	4
191	Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. <b>2021</b> , 35, 239-254	4
190	Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy. <b>2021</b> , 199, 199-211	0
189	Beta-blocker-associated hypoglycaemia: New insights from a real-world pharmacovigilance study. <b>2021</b> , 87, 3320-3331	4
188	A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database. <b>2021</b> , 1	2
187	Hyponatremia Following Antipsychotic Treatment: In Silico Pharmacodynamics Analysis of Spontaneous Reports From the US Food and Drug Administration Adverse Event Reporting System Database and an Updated Systematic Review. <b>2021</b> , 24, 477-489	2
186	Overview of HIV treatment failure in Africa using the WHO Pharmacovigilance data. <b>2021</b> , 26, 530-534	
185	Worsening of myasthenia due to antiepileptic, antipsychotic, antidepressant, and sedative medication: An estimation of risk based on reporting frequency. <b>2021</b> , 28, 2349-2356	1
184	Change Point Analysis for Detecting Vaccine Safety Signals. <b>2021</b> , 9,	2
183	Monitoring vaccine safety by studying temporal variation of adverse events using vaccine adverse event reporting system. <b>2021</b> , 15,	0
182	Evaluation of the Expression Profile of Irinotecan-Induced Diarrhea in Patients with Colorectal Cancer. <b>2021</b> , 14,	2
181	Effect of antipsychotics on breast tumors by analysis of the Japanese Adverse Drug Event Report database and cell-based experiments. <b>2021</b> , 7, 13	1
180	Neuroleptic malignant syndrome associated with long-acting injectable versus oral second-generation antipsychotics: Analyses based on a spontaneous reporting system database in Japan. <b>2021</b> , 231, 42-46	0
179	Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase. <b>2021</b> , 77, 1513-1521	2
178	Nephrotoxicity in immune checkpoint inhibitor therapy: a pharmacovigilance study. <b>2021</b> ,	0
177	Visual-vestibular mismatch correlates with headache. <b>2021</b> , 31, 173-180	4
176	Ocular Safety Profile of BRAF and MEK Inhibitors: Data from the World Health Organization Pharmacovigilance Database. <b>2021</b> , 128, 1748-1755	2
175	Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database. <b>2021</b> , 43, 1508-1515	1

174	VAERS data reveals no increased risk of neuroautoimmune adverse events from COVID-19 vaccines.	0
173	Pulmonary adverse drug event data in hypertension with implications on COVID-19 morbidity. <b>2021</b> , 11, 13349	2
172	Spontaneous and Immune Checkpoint Inhibitor-Induced Autoimmune Diseases: Analysis of Temporal Information by Using the Japanese Adverse Drug Event Report Database. <b>2021</b> , 41, 615-627	0
171	Data mining for detecting signals of adverse drug reaction of doxycycline using the Korea adverse event reporting system database. <b>2021</b> , 1-6	
170	Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases. <b>2021</b> , 134, 14-21	17
169	Risk of Bleeding Associated with Antidepressant Drugs: The Competitive Impact of Antithrombotics in Quantitative Signal Detection. <b>2021</b> , 8, 547-554	2
168	Evaluation of Potential Complications of Interstitial Lung Disease Associated With Antiandrogens Using Data From Databases Reporting Spontaneous Adverse Effects. <b>2021</b> , 12, 655605	2
167	Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data. <b>2021</b> , 43, 1116-1122	1
166	The Impact of Serotonin Transporter Binding Affinity on the Risk of Bleeding Related to Antidepressants. <b>2021</b> , 41, 470-473	0
165	The risk of worsening of myasthenia by cardiovascular medication as reflected by reporting frequency. <b>2021</b> , 28, 2965-2970	0
164	Relative Risk Analysis of Liver-related Adverse Drug Reactions in Children Based on China's National Spontaneous Reporting System. <b>2021</b> , 234, 85-91	1
163	Augmenting aer2vec: Enriching distributed representations of adverse event report data with orthographic and lexical information. <b>2021</b> , 119, 103833	
162	Ocular surface disorders associated with the use of dupilumab based on WHO Vigibase. <b>2021</b> , 11, 14293	0
161	Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database. <b>2021</b> , 162, 496-505	3
160	Disproportionality analysis of reported drug adverse events to assess a potential safety signal for pentavalent vaccine in 2019 in El Salvador. <b>2021</b> , 39, 4849-4855	0
159	Signal detection of drospirenone-containing oral contraceptives: a disproportionality analysis using the Korea Adverse Event Reporting System Database, 2008-2017. <b>2021</b> , 11, e045948	0
158	Patient Drug Database: Construction of Database for Patient Leading Drug Side Effects Exploration Using Patient Generated Health Data. <b>2021</b> , 46, 315-325	
157	Safety of Memantine in Combination with Potentially Interactive Drugs in the Real World: A Pharmacovigilance Study Using the Japanese Adverse Drug Event Report (JADER) Database. <b>2021</b> , 82, 1333-1344	1

156	Risk of neuropsychiatric adverse events associated with varenicline treatment for smoking cessation among Dutch population: A sequence symmetry analysis. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2021</b> ,	2.6	2
155	Stress cardiomyopathy (Takotsubo syndrome) in patients who received adrenergic agonist drugs: A pharmacovigilance study using the Japanese Adverse Drug Event Report (JADER) database. <b>2022</b> , 79, 36-41		3
154	Geriatrics on beers criteria medications at risk of adverse drug events using real-world data. <b>2021</b> , 154, 104542		0
153	Associations between osteoporosis and drug exposure: A post-marketing study of the World Health Organization pharmacovigilance database (VigiBase <sup>®</sup> ). <b>2021</b> , 153, 116137		2
152	Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study). <b>2021</b> , 16, 741-748		3
151	Adverse outcomes associated with the treatment of Toxoplasma infections. <b>2021</b> , 11, 1035		6
150	Pharmacoepidemiology. <b>2014</b> , 1875-1925		8
149	Association of hepatitis B with antirheumatic drugs: a case-control study. <b>2013</b> , 23, 694-704		12
148	Neuropsychiatric adverse events of chloroquine: A real-world pharmacovigilance study using the FAERS database.		2
147	Opportunities for Web-based Drug Repositioning: Searching for Potential Antihypertensive Agents with Hypotension Adverse Events. <b>2016</b> , 18, e76		10
146	The Association between Ranitidine Use and Gastrointestinal Cancers. <b>2020</b> , 13,		5
145	Improved Detection Criteria for Detecting Drug-Drug Interaction Signals Using the Proportional Reporting Ratio. <b>2020</b> , 14,		3
144	Signal Detection of Adverse Drug Reaction of Zolpidem Using the Korea Adverse Event Reporting System Database. <b>2018</b> , 6, 43-49		1
143	Use of Secondary Population-Based Databases to Evaluate the Safety of Medications. <b>2008</b> ,		1
142	New Strategy for Pharmacovigilance Using Data-Mining Methods in Pharmaceuticals and Medical Devices Agency. <b>2010</b> , 15, 23-30		7
141	Detection of Signals of Convulsion-inducing Effect for Fluoroquinolone Antibiotics Alone and with Co-administration of Nonsteroidal Anti-inflammatory Drugs in Association with Aging Using Japanese Adverse Drug Event Reporting Database. <b>2019</b> , 50, 203-209		1
140	Signal Detection of Serious Infections Following Treatment with Biologics for Rheumatoid Arthritis:. <b>2014</b> , 40, 586-594		2
139	Analysis of Effects of the Diuretics on Levels of Blood Potassium and Blood Sodium with Angiotensin Receptor Blockers and Thiazide Diuretics Combination Therapy: Data Mining of the Japanese Adverse Drug Event Report Database, JADER. <b>2015</b> , 41, 488-496		9



138	Syndromic surveillance in companion animals utilizing electronic medical records data: development and proof of concept. <b>2016</b> , 4, e1940	9
137	Clozapine and hematologic adverse reactions: Impact of the Risk Evaluation and Mitigation Strategy program. <b>2020</b> , 10, 70-75	4
136	Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study. <b>2021</b> ,	10
135	Drug-Induced Respiratory Disease in Cardiac Patients. <b>2009</b> , 131-157	
134	Flexible Ubiquitous Learning Management System Adapted to Learning Context. <b>2010</b> , 48-59	0
133	Data Mining in Pharmacoepidemiological Databases. <b>2013</b> , 351-364	
132	Signal Detection of hepatitis B and hepatitis C by molecularly-targeted drugs for cancer:. <b>2014</b> , 40, 268-277	3
131	Analysis of Adverse Events Associated with Angiotensin Receptor Blockers and Hydrochlorothiazide Fixed-dose Combination: Data Mining of the Japanese Adverse Drug Event Report Database, JADER. <b>2015</b> , 41, 347-354	3
130	Development and Application of an Alert System to Detect Cases of Food Poisoning in Japan. <b>2016</b> , 11, e0156395	
129	Risk of Drug-Induced Accidents and Injuries in Elderly Patients Treated with Specific Drugs Rather than Polypharmacy : Analyses of the Japanese Adverse Drug Event Report Database. <b>2019</b> , 31, 125-137	
128	Drug-Associated Delirium Identified in The Food and Drug Administration Adverse Events Reporting System. <b>2019</b> , 1-7	1
127	aer2vec: Distributed Representations of Adverse Event Reporting System Data as a Means to Identify Drug/Side-Effect Associations.	1
126	Evaluation of a novel syndromic surveillance system for the detection of the 2007 melamine-related nephrotoxicosis foodborne outbreak in dogs and cats in the United States. <b>2020</b> , 8, e9093	
125	Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database. <b>2021</b> ,	3
124	Detection and Evaluation of Adverse Drug Reaction Signals of Antidepressants Based on FDA Adverse Event Reporting System Database. <b>2020</b> , 09, 17-25	
123	Deep learning from spontaneous reporting systems data to detect ADR signals. <b>2020</b> ,	0
122	Spontaneous Reporting System Modelling for the Evaluation of Automatic Signal Generation Methods in Pharmacovigilance. <b>2007</b> , 75-92	
121	1.Spontaneous Report Database and Case-control Studies. <b>2020</b> , 25, 56-63	

120	Automatic adverse drug events detection using letters to the editor. <b>2012</b> , 2012, 1030-9	5
119	Discovering adverse drug events combining spontaneous reports with electronic medical records: a case study of conventional DMARDs and biologics for rheumatoid arthritis. <b>2017</b> , 2017, 95-103	4
118	Safety Profile of Levonorgestrel: A Disproportionality Analysis of Food and Drug Administration Adverse Event Reporting System (Faers) Database. <b>2018</b> , 19, 152-156	2
117	Detecting Signals of Dietary Supplement Adverse Events from the CFSAN Adverse Event Reporting System (CAERS). <b>2019</b> , 2019, 258-266	3
116	: Distributed Representations of Adverse Event Reporting System Data as a Means to Identify Drug/Side-Effect Associations. <b>2019</b> , 2019, 717-726	3
115	Retrofitting Vector Representations of Adverse Event Reporting Data to Structured Knowledge to Improve Pharmacovigilance Signal Detection. <b>2020</b> , 2020, 383-392	1
114	Risk of candidiasis associated with interleukin-17 inhibitors: A real-world observational study of multiple independent sources.. <b>2022</b> , 13, 100266	7
113	Association between the use of sodium-glucose co-transporter-2 inhibitors and drug-induced acute kidney injury: analysis of two databases. <b>2021</b> ,	0
112	Hepatotoxicity-Related Adverse Effects of Proton Pump Inhibitors: A Cross-Sectional Study of Signal Mining and Analysis of the FDA Adverse Event Report System Database. <b>2021</b> , 8, 648164	3
111	Association Between Pentosan Polysulfate Sodium and Retinal Disorders. <b>2021</b> ,	0
110	TEDAR: Temporal dynamic signal detection of adverse reactions. <b>2021</b> , 122, 102212	
109	An AdaBoost-Inspired Ensemble Method for ADR Signal Detection. <b>2020</b> ,	0
108	Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System.. <b>2022</b> , 2022, 9866486	0
107	Adverse Events During Pregnancy Associated With Entecavir and Adefovir: New Insights From a Real-World Analysis of Cases Reported to FDA Adverse Event Reporting System.. <b>2021</b> , 12, 772768	0
106	Social Media Analytics for Pharmacovigilance of Antiepileptic Drugs.. <b>2022</b> , 2022, 8965280	
105	Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States.. <b>2021</b> , 9, 756633	5
104	Active comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 (SGLT2) inhibitors.. <b>2021</b> ,	0
103	Thromboembolism and Oral Contraceptives During the COVID-19 Pandemic: A Disproportionality Analysis Within the Spanish Pharmacovigilance Database.. <b>2022</b> , 1	0

102	Analysis of Water Intoxication by Drugs Using the Japanese Adverse Drug Event Report (JADER) Database. <b>2021</b> , 47, 91-95	
101	Drug-Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data.. <b>2022</b> , 45, 287	1
100	Colistin-associated Stevens-Johnson syndrome and toxic epidermal necrolysis reactions: a retrospective case-non-case pharmacovigilance study.. <b>2022</b> ,	0
99	Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database.. <b>2022</b> , 20, 12	1
98	Challenges and Opportunities of Real-World Data: Statistical Analysis Plan for the Optimise:MS Multicenter Prospective Cohort Pharmacovigilance Study.. <b>2022</b> , 13, 799531	
97	Age-Associated Risk of Liver-Related Adverse Drug Reactions.. <b>2022</b> , 9, 832557	0
96	Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS).. <b>2022</b> , 1	4
95	Discovering Drug-Drug Associations in the FDA Adverse Event Reporting System Database with Data Mining Approaches. <b>2021</b> ,	
94	COVID Vaccine and Cardiovascular Risks: A Natural Language Analysis of Vaccine Adverse Event Reports. <b>2021</b> ,	
93	Time to onset of drug-induced parkinsonism: Analysis using a large Japanese adverse event self-reporting database.. <b>2022</b> ,	0
92	Neurocognitive impairment associated with traditional and novel androgen receptor signaling inhibitors – androgen deprivation therapy: a pharmacovigilance study.. <b>2022</b> ,	
91	Cancer risk in individuals with autism spectrum disorder.. <b>2022</b> ,	0
90	Image_1.TIF. <b>2018</b> ,	
89	Image_2.TIF. <b>2018</b> ,	
88	Image_3.TIF. <b>2018</b> ,	
87	Image_4.TIF. <b>2018</b> ,	
86	Image_5.TIF. <b>2018</b> ,	
85	Table_1.docx. <b>2018</b> ,	

84 Table\_2.docx. **2018,**

83 Image\_1.JPEG. **2018,**

82 Image\_2.JPEG. **2018,**

81 Image\_3.JPEG. **2018,**

80 Image\_4.JPEG. **2018,**

79 Table\_1.DOCX. **2018,**

78 Increased risk of urinary tract infection and pyelonephritis under concomitant use of sodium dependent glucose cotransporter 2 inhibitors with antidiabetic, antidyslipidemic and antihypertensive drugs: An observational study.. **2022,** 0

77 Acontecimientos adversos en embarazadas con la vacuna tetravalente contra la gripe obtenida de cultivos celulares. **2022,**

76 Risk of hepatitis B virus reactivation following treatment with abatacept: A retrospective study of international pharmacovigilance databases. **2022,** 48, 101425 1

75 A Disproportionality Analysis for Association of Systemic Capillary Leak Syndrome with COVID-19 Vaccination Using the World Health Organization Pharmacovigilance Database. **2022,** 10, 835 0

74 Association of Cerebral Venous Thrombosis with mRNA COVID-19 Vaccines: A Disproportionality Analysis of the World Health Organization Pharmacovigilance Database. **2022,** 10, 799 3

73 Risk of systemic vasculitis following mRNA COVID-19 vaccination: a pharmacovigilance study. 1

72 Adverse Drug Reactions of Intranasal Corticosteroids in the Netherlands: An Analysis from the Netherlands Pharmacovigilance Center. 0

71 Comparative Safety Signal Assessment of Hospitalization Associated With the Use of Atypical Antipsychotics. **2022,** 13, 0

70 Association between Anti-Osteoporotic Drugs and Risk of Acute Kidney Injury: A Cross-Sectional Study Using Disproportional Analysis and a Pharmacovigilance Database.

69 Association of Aggression and Antiepileptic Drugs: Analysis Using the Japanese Adverse Drug Event Report (JADER) Database. **2022,** 45, 720-723 0

68 Opioid-induced respiratory depression and risk factors in a tertiary hospital: A retrospective study. **2022,**

67 Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data. 13, 1

- 66 A Pharmacovigilance Study of Terbinafine Indication and Liver Enzyme Elevation." **2022,**
- 65 Analysis of adverse drug events in pulmonary Mycobacterium avium complex disease using spontaneous reporting system. **2022, 22,**
- 64 Hepatitis B Virus Reactivation and Mycobacterial Infections Associated With Ustekinumab: A Retrospective Study of an International Pharmacovigilance Database. 13,
- 63 A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS). ○
- 62 Cardiovascular adverse events in oncology trials: understanding and appreciating the differences between clinical trial data and real-world reports. **2022, 8,**
- 61 A disproportionality analysis for the association of central nervous system demyelinating diseases with COVID-19 vaccination using the World Health Organization pharmacovigilance database. 135245852211093
- 60 Associations of Guillain-Barré syndrome with coronavirus disease 2019 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database. ○
- 59 Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system. **2022, 50, 101535** ○
- 58 Adverse event classification and signal detection of data from the customer service and pharmacovigilance of a multinational veterinary pharmaceutical company. **2022, 206, 105704**
- 57 Decoding kinase-adverse event associations for small molecule kinase inhibitors. **2022, 13,** ○
- 56 Evaluation of Thyroid Dysfunction Associated with the Use of Molecular Targeted Antineoplastic Drugs Using the Japanese Adverse Drug Event Report Database. **2021, 47, 437-444**
- 55 Short communication: Comments on hair disorders associated with dupilumab based on VigiBase. **2022, 17, e0270906**
- 54 Generalised weibull model-based approaches to detect non-constant hazard to signal adverse drug reactions in longitudinal data. 13,
- 53 Temporal Pattern of Cardiac Adverse Events Associated with EGFR-TKIs in Lung Cancer Patients: A Pharmacovigilance Analysis. ○
- 52 Potential safety signals for antibacterial agents from the Brazilian national pharmacovigilance database (Vigimed/VigiFlow). 13, ○
- 51 Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system. 13, 1
- 50 Detecting early safety signals of infliximab using machine learning algorithms in the Korea adverse event reporting system. **2022, 12,** ○
- 49 A tree-based scan statistic for zero-inflated count data in post-market drug safety surveillance. **2022, 12,** 1

48	COVID-19 vaccine and menstrual conditions in female: data analysis of the Vaccine Adverse Event Reporting System (VAERS). <b>2022</b> , 22,	1
47	A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab. 1-4	0
46	Is Omalizumab Related to Ear and Labyrinth Disorders? A Disproportionality Analysis Based on a Global Pharmacovigilance Database. <b>2022</b> , 12, 2434	0
45	Associations of neuralgic amyotrophy with COVID -19 vaccination: Disproportionality analysis using the World Health Organization pharmacovigilance database.	0
44	Comment on: "A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)".	0
43	Adverse Reaction Profiles Related to Gastrointestinal Bleeding Events Associated with BCR-ABL Tyrosine Kinase Inhibitors. <b>2022</b> , 58, 1495	0
42	Hepatobiliary calculi associated with ceftriaxone treatment: An analysis of FAERS data from 2004 to 2021. <b>2022</b> ,	0
41	Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. <b>2022</b> , 17, e0272022	1
40	Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system. 13,	0
39	Do antibody-drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study. 13,	0
38	Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase®).	0
37	Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS. <b>2022</b> , 13, 204209862211432	0
36	Adverse events in pregnant women with the tetravalent influenza vaccine obtained from cell cultures. <b>2022</b> ,	0
35	Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19. <b>2022</b> , 15, 1472	0
34	Immunogenomic correlates of immune-related adverse events for anti-programmed cell death 1 therapy. 13,	0
33	Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System.	0
32	Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database. 13,	0
31	Association between use of febuxostat and muscle injury: A disproportionality analysis and meta-analysis of randomized controlled trials.	0

- 30 Hemorrhagic and thrombotic adverse events associated with emicizumab and extended half-life FVIII replacement drugs: EudraVigilance data of 2021. **2023**, ○
- 29 Cardiac adverse events in bisphosphonate and teriparatide users: An international pharmacovigilance study. **2023**, 168, 116647 ○
- 28 Association of Pulmonary Sepsis and Immune Checkpoint Inhibitors: A Pharmacovigilance Study. **2023**, 15, 240 ○
- 27 An open-source platform integrating emerging data sources to support multi-modal active pharmacovigilance. 2, ○
- 26 Optimize and Strengthen Machine Learning Models Based on in Vitro Assays with Mechanistic Knowledge and Real-World Data. **2023**, 183-198 ○
- 25 Increased odds of mortality from non-malignant respiratory disease and lung cancer are highest among US coal miners born after 1939. oemed-2022-108539 ○
- 24 Delta-8, a Cannabis-Derived Tetrahydrocannabinol Isomer: Evaluating Case Report Data in the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. Volume 15, 25-38 ○
- 23 Drugs That Interact With Colchicine Via Inhibition of Cytochrome P450 3A4 and P-Glycoprotein: A Signal Detection Analysis Using a Database of Spontaneously Reported Adverse Events (FAERS). 106002802211480 ○
- 22 Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System. ○
- 21 Cardiac toxicity associated with pharmacokinetic drug-drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report. ○
- 20 Real-world evidence of autoimmune hepatitis following COVID-19 vaccination: A population-based pharmacovigilance analysis. 14, ○
- 19 Electrolyte Disorders Associated with Piperacillin/Tazobactam: A Pharmacovigilance Study Using the FAERS Database. **2023**, 12, 240 ○
- 18 Myopericarditis Associated with the Novavax COVID-19 Vaccine (NVX-CoV2373): A Retrospective Analysis of Individual Case Safety Reports from VigiBase. ○
- 17 Potential and Pitfalls of Pharmacovigilance Databases in Oncology. **2023**, 5, 99-101 ○
- 16 Proton Pump Inhibitors and Rhabdomyolysis: Analysis of Two Different Cross-Sectional Databases. 106002802311562 ○
- 15 Depression and suicidality with VMAT2 inhibitors in tardive dyskinesia A signal detection from the FDA Adverse Events Reporting System. **2023**, 2, ○
- 14 An evaluation of adverse drug reactions and outcomes attributed to kratom in the US Food and Drug Administration Adverse Event Reporting System from January 2004 through September 2021. ○
- 13 Comment on: Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis ○

- 12 Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: A systematic literature review of published case reports and disproportionality analysis based on the FAERS database. 14, ○
- 11 Dysautonomia associated with immune checkpoint inhibitors. ○
- 10 Pharmacoepidemiology. 2022, 1-55 ○
- 9 Updated insights on dementia-related risk of sacubitril/valsartan: A real-world pharmacovigilance analysis. ○
- 8 Statistical methods for exploring spontaneous adverse event reporting databases for drug-host factor interactions. 2023, 23, ○
- 7 Bayesian generalized linear low rank regression models for the detection of vaccine-adverse event associations. ○
- 6 Comparative cardiotoxicity risk of pembrolizumab versus nivolumab in cancer patients undergoing immune checkpoint inhibitor therapy: A meta-analysis. 13, ○
- 5 Appendicitis Associated With Clozapine. Publish Ahead of Print, ○
- 4 Abemaciclib pharmacovigilance analysis:a real-world analysis of post-marketing surveillance Data. ○
- 3 Biologics for asthma have risk of anaphylactic reactions and serious? : A pharmacovigilance study based on a global real-world database. ○
- 2 PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS). 1-11 ○
- 1 Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. 2023, 59, 101967 ○